{"slug":"issue-92","tag":"issue-92","variants":["issue-92"],"description":"No description yet","count":1,"kinds":{"trial":1},"related":[{"slug":"pipeline","tag":"pipeline","shared":1}],"records":[{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","status":"positive","tldr":"VISION showed that a once-daily MET tablet shrank about half of advanced lung cancers driven by a MET exon 14 skipping mutation, whether the mutation was found in blood or in tumour tissue, which led to tepotinib's approvals in Japan, the United States and Europe."}]}